TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Preterm Infants' Paracetamol Study
Brief Summary: Present randomized, controlled, double-blind trial investigates the efficacy and safety of early (\<24 h) intravenous paracetamol therapy for pain medication in very small premature infants. This phase 2 drug study focuses on the efficacy and safety of short-term use. The pharmacokinetics and pharmacodynamics of paracetamol, as well as the long-term effects, are studied.

This study recruits preterm infants born less than 32 weeks gestational age and treated at the neonatal intensive care unit of Oulu University Hospital. The informed consent is asked from all parents. The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL or placebo, 0.45% saline solution. The loading dose is 20 mg/kg, and the maintenance dose 7.5 mg/kg every 6 hours for 4 days. The exact date of the closure of ductus is studied by repeated echocardiographic examinations. The symptoms of pain are screened by a pain scale of preterm infants (NIAPAS). Patients are monitored for signs of possible side effects. After discharge from hospital, patients are examined at follow-up clinic for the first year every 3 months and at 2 years of age.


Options:
A: Inclusion Criteria:

* Very low birthweight infants
B: Inclusion Criteria:

1. Gestational age ≤ 35 weeks
2. Aged 2-7 days with color Doppler echocardiographic evidence of PDA
3. Urine output more than 1 ml/kg/hr
4. Creatinine concentration level less than 1.8 mg/dl

Exclusion Criteria:

Neonates who have one or more of the following criteria were excluded from the study:

1. Congenital heart diseases of any type including

   * Pulmonary stenosis
   * Anomalus in pulmonary venous drainage
   * Ventricular septal defect
2. Major congenital anomalies as hydrops fetalis
3. Low platelets count (less than 60, 000/mm3)
C: Inclusion Criteria:

* Birth weight below 1250 gram
* Diagnosed patent ductus arteriosus by Echocardiographic examination

Exclusion Criteria:

* Accompanied other congenital cardiac anomalies
* Urine output of less than 1 ml/kg/h during the preceding 8 h,
* Serum creatinine level \>1.6 mg/dl,
* Platelet count \<60,000/mm3,
* Liver failure,
* Hyperbilirubinemia requiring exchange transfusion
* Severe intracranial bleeding (Grade III - IV)
* Intestinal abnormality and necrotising enterocolitis
D: Inclusion Criteria:

* preterm infants born \< 32 weeks gestational age

Exclusion Criteria:

* congenital malformation
* lethal disease
* chromosomal abnormality
* persistent pulmonary hypertension of a newborn

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Double-blind Randomized Controlled Trial of a Thickened Amino-acid-based Formula in Children Allergic to Cow's Milk and to Protein Hydrolysates
Brief Summary: The purpose of this study is to evaluate the impact of a new Amino-acid based formula on allergic symptoms and growth of infants with cow's milk protein allergy and intolerant to extensively hydrolysed formulas;


Options:
A: Inclusion Criteria:

* birth weight 400 to 1250 grams
* 24 0/7 to 30 6/7 weeks gestational age

Exclusion Criteria:

* chromosomal, structural, metabolic, endocrine, or renal abnormalities that could affect growth
* infants \>18 hours of age
* infants in extremis who are unlikely to survive past 72 hours
B: * Clinically stable, very low birth weight infants (750-1,500 grams)
* Normal blood glucose values OR Blood glucose greater than 175 mg/dL
* No prior insulin
* No sepsis Oxygen supply less than 30% Normal acid base status
* No malformation
* No discernible diseases
C: Inclusion Criteria:

* less than 18 months old
* with a proven cow's milk protein allergy by a double blind placebo controlled food challenge or a positive Skin prick test (\>=6mm) or specific immunoglobulin E \>= 5 kilo-unit/L or combination
* still symptomatic while fed an extensively hydrolysed formula

Exclusion Criteria:

* Exclusively breast fed infants
* non allergic digestive enteropathy
D: Inclusion Criteria:

* mechanically ventilated neonates of all gestational ages and birth weights
* less than 1 month of postnatal age admitted to the NICU
* SNAP (Score of Neonatal Acute Physiology) \> 10
* projected requirement for continued parenteral nutrition of at least 1 week duration

Exclusion Criteria:

* renal or hepatic failure
* requiring insulin administration
* requiring extracorporeal life support
* known inherited metabolic disorders
* known uniformly fatal congenital anomalies

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care: The mPeer2Peer Study
Brief Summary: The purpose of the mPeer2Peer Study (mP2P) is to see if we can use a smartphone and a Peer Navigator (PN) to improve medical care for HIV-positive people who have been out of HIV care for over one year.


Options:
A: Inclusion Criteria:

* History of current or former injection drug use
* No clinic visits with an HIV provider in the preceding 12 months
* Not taking ART
* HIV RNA level of greater than 1,000 copies/mL
* Agree to attend at least one HIV care visit at the Johns Hopkins Moore clinic

Exclusion Criteria:

* Any medical or psychiatric condition that would interfere with the participant's ability to comply with study procedures or make participation unsafe
* Current enrollment in another HIV retention-in-care study
B: Inclusion Criteria:

* Pregnant women in Baltimore, Virginia, and Missouri if needed.
* Speak English or Spanish
* Eligible for home visitation.

Exclusion Criteria:

* Women who begin participation in a perinatal home visiting program after the baby is born.
* Women who do not speak English or Spanish.
C: Inclusion Criteria:

* Parents/legal guardians/carers of infants aged 6-8 weeks
* First or subsequent born infants

Exclusion Criteria:

* Parents/legal guardians/carers of infants with known medical conditions requiring special diets
* Mothers who have a diagnosis of post-natal depression (PND) or who score moderate PND or above on health visitor applied screening tools (EPDS \>13) (PHQ-9 \>10) or anxiety (GAD-7 score \>10)
* Infants born \<32 weeks gestation
* Infants born 32-40 weeks whose birth weight is less than 2nd centile
* Infants born at term (40 weeks) who weigh less than 2.5 kg
* Parents/legal guardians/carers who lack sufficient command of English to complete questionnaires where no face to face translation is available
D: Inclusion Criteria:

* pregnant women with gestation of 28 weeks or less, making their first antenatal consultation

Exclusion Criteria:

* no exclusion criteria has been developed. All women that qualify are eligible for recruitment

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Promoting Adherence to Sleep Apnea Treatment Through Health Education Among Blacks With Metabolic Syndrome
Brief Summary: This is a randomized controlled Trial to evaluate effect of a culturally and linguistically tailored, telephone-delivered behavioral intervention on adherence to recommended assessment and treatment of sleep apnea in Blacks with Metabolic Syndrome. The investigators believe low awareness of Sleep Apnea and the risk it imposes to an individual health plays an important role in underdiagnosis and low adherence to treatment among Blacks. Hence, culturally and linguistically tailored health education will decrease the knowledge gap and improve adherence to recommended assessment and treatment of sleep Apnea. the investigators believe the effect of adherence to treatment of Sleep apnea is shown to improve the components of Metabolic syndrome and hence promote well control of Hypertension, Diabetes, weight, triglyceride and cholesterol.


Options:
A: Inclusion Criteria:

* Clinical suspicion of obstructive sleep apnea (OSA)
* Appropriate for home sleep testing
* No prior use of CPAP or other therapies for OSA

Exclusion Criteria:

* Commercial drivers
* Complex sleep disorders (e.g. CSA)
* No DME (durable medical equipment) insurance coverage
* Declines CPAP therapy
B: Inclusion Criteria:

* Age \> 18 years
* African American / carribean American / African.

Exclusion Criteria:

* Pregnancy or breastfeeding
* Involvement with other study
* Unable to understand and sign the informed consent form
* Heart attack or stroke within the past 12 weeks
* Diagnosed with Obstructive Sleep Apnea and/or on treatment
C: Inclusion Criteria:

* self-reported race/ethnic minority
* ages ≥18 years
* accessible by telephone
* consent to participate, which includes permission to release medical record information
* A positive screening for OSA is necessary to be enrolled in the intervention protocol.

Exclusion Criteria:

* are involved in another sleep study.
* are unable to understand and sign this informed consent form.
* know someone who is participating in this study.
* had a heart attack or stroke within the past 12 weeks.
* do not identify yourself as a racial/ethnic minority.
* are pregnant.
* Refuse to use the ARESTM home sleep test device.
* Refuse to use the WatchPATTM home sleep test device.
* are not at risk for sleep apnea.
D: Inclusion Criteria:

* Adults (18-70 yrs of age) with a subacute stroke (1-12 months)
* Diagnosis of sleep apnea and acceptance of CPAP therapy:

Exclusion Criteria:

* Patients with sopor/coma
* Any form of dementia (Mini-Mental State Examination \<20)
* Previously diagnosed sleep apnea and established CPAP therapy
* Purely central sleep apnea
* Chronic obstructive pulmonary disease more than Gold III
* Cancer
* Severe kidney diseases
* Coexisting causes of daytime sleepiness (e.g. narcolepsy, night or rotating shift-work; self-reported average sleep duration \<4 h)
* A major psychiatric or any other acute medical condition
* Patients unable or unwilling to comply with the protocol

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effect of Maternal Supplementation With DHA During Pregnancy and Lactation on the Development of the Term Newborn
Brief Summary: In the present study, we evaluate the effect of the mother suplementación with DHA during the gestation and lactation on diverse aspects of the development of newborn. The effect on the oxidative stress, inflammatory signaling, bone turnover and piscomotor and visual development was studied. Women will in the sixth month of pregnancy, consume a diet balanced during last 3 months of pregnancy and the whole lactation. In addition the women will divide in two groups: one will receive a supplement of docosahexaenoic acid (DHA) to evaluate the effects on the development of the newborn child; whereas another group will receive a placebo. Different samples of blood of the mother and of mother milk will be taken and we will correlating her lipidic profile with the brain development of the newborn child, evaluated by different tests.


Options:
A: Inclusion Criteria:

1. Consent
2. mother with normal gestation.

Exclusion Criteria:

1. Risk factors during gestation.
2. Lactose intolerance
3. systemic illness.
4. Kwashiorkor.
5. Metabolic illness.
6. Foetal pathologies
B: Inclusion Criteria:

* Pregnant females 18 years and older 12 to 20 weeks gestation at study entry
* Agree to consume study capsules and a typical prenatal supplement of 200 mg DHA
* Available by telephone
* Able to speak and read in either English or Spanish language

Exclusion Criteria:

* Expecting multiple infants
* Gestational age at baseline \<12 weeks or \>20 weeks
* Unable or unwilling to agree to consume capsules until delivery
* Unwilling to discontinue use of another prenatal supplement that contains greater than or equal to 200 mg DHA per day
* Women with allergy to any component of DHA product (including algae), soybean oil or corn oil
C: Inclusion Criteria:

* Pre-pregnant body mass index greater than 25
* Singleton pregnancy
* Speaks English

Exclusion Criteria:

* High intake of DHA foods (i.e., more than 1 fish meal per week, use of DHA-fortified foods, or use of any supplements that contain DHA)
* Concurrent inflammatory, vascular, or metabolic disease, including diabetes, polycystic ovary disease, collagen vascular disease, inflammatory bowel disease, or infection
* Current or previous use of tobacco, street drugs, or medications known to affect inflammatory markers, including corticosteroids
* Excessive weight gain or loss before pregnancy (more than 20 pounds), including weight loss due to bariatric surgery
* Plans to leave the area during the study period
* Inability to travel to General Clinical Research Center
D: Inclusion Criteria:

* 12-16 weeks gestation
* Low risk pregnancy
* Expected to deliver single full term
* No maternal metabolic or infectious disease
* No known fetal complications.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Per Operative Fluid Optimisation Comparison of an Automated Closed-Loop System Versus Current Practice in High Risk Abdominal Surgical Patient. A Prospective, Randomized Clinical Trial.
Brief Summary: Dynamic parameters like pulse pressure variation have been shown to be accurate predictors of fluid responsiveness. Hemodynamic optimization based on fluid management and stroke volume optimization have been shown to improve patient outcomes, especially for moderate and high risk abdominal surgical patients. A novel closed-loop fluid administration system based on multi-parameter hemodynamic monitoring have been described recently. This prospective, randomized, surgeon and patient blinded study aims at comparing the cardiac output provided by either this closed-loop system or the anesthesiologist team in high-rish surgical patient elected for abdominal surgery at Pierre Bénite University Hospital, Hospices Civils of Lyon, France. Primary endpoint is the mean indexed cardiac output during surgery per group. We will also compare hemodynamic parameter (cardiac output, stroke volume, blood pressure heart rate...) and patient's outcomes (morbidity, mortality, transfusion rate, hospital length of stay) between groups


Options:
A: Inclusion Criteria:

* Elective major abdominal surgery
* Patient physical status ASA 2-4
* General anesthesia with positive pressure ventilation
* High risk surgical patient with a per operative Vigileo® cardiac output monitoring decided a priori.

Exclusion Criteria:

* Pregnant female
* Intraoperative hyperthermic chemotherapy procedure
* Patient physical status ASA more than 4
* Patient with allergy to hydroxyethyl starch
* Cardiac arrhythmia
* ventilation with tidal volume inferior 7mL/Kg
B: Inclusion Criteria:

* age greater than 18 years
* signed informed consent
* listed for deceased donor transplantation.

Exclusion Criteria:

* esophageal surgery or cancer
* esophageal stricture, varices or diverticulum
* upper airway surgery
* coarctation of the aorta
* significant valvular heart disease
* clinically significant cardiac arrhythmias
* patient randomized to other trials with an outcome variable of delayed graft function or early graft function will also be excluded
C: Inclusion Criteria:

* American Society of Anesthesiologists physical class I-III patients over the age of 18 years
* Presenting for elective open repair of abdominal aortic aneurysms.

Exclusion Criteria:

* Weight \>120kg
* Known or suspected valvular aortic insufficiency
* Renal Dysfunction (serum creatinine \>150 μmol/l)
* Pre-existing bowel dysfunction
* Active congestive heart failure
D: Inclusion Criteria:

* Laparoscopic and/or robotic elective abdominal surgery( colorectal, gynecological, urological)

Exclusion Criteria:

* Intraoperative invasive monitoring (arterial line)
* Open colorectal surgery (laparotomy)
* Emergency surgery
* Expected intraoperative blood loss greater than 1000ml
* Arrhythmia (e.g. atrial fibrillation)

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Correlational Study of Pulse Pressure Variation in Various Tidal Volume in Mechanically Ventilated Patients Under General Anaesthesia
Brief Summary: Mesquida, J et al showed there was a significant linear correlation between pulse pressure variations under tidal volume 6 ml/kg and 8 ml/kg in patients after the resuscitation phase of severe sepsis and septic shock. No study revealed the actual relationship between various PPV under different VT. So we hypothesized that there were relationship between various PPV in different tidal volume settings. The objective of this study was to examine the relationship between various PPV.


Options:
A: Inclusion Criteria:

* Age: 18-65 years
* Chest X-ray: no infiltrates
* Duration of mechanical ventilation from the admission to ICU to the clinical diagnosis of brain death \< 5 days
* No history of Smoking (1 pack/day for 20 years; 1/2 pack/day for 40 years; 2 packs/day for 10 years)
* No history of Asthma
* No history of COPD
* No history of Trauma
* No history of Thoracic surgery

Exclusion Criteria:

* Evidence of aspiration (chest X-ray or bronchoscopy) or sepsis
* Purulent secretions (tracheal suction or bronchoscopy)
* Sputum Gram stain with bacteria, fungus, significant number of WBC
B: Inclusion Criteria:

scheduled for elective abdominal surgeries ASA (American Society of Anesthesiologists) I or II BMI 18-25 preoperative examination is normal

Exclusion Criteria:

acute lung injure acute respiratory distress syndrome cardiovascular diseases neurological disease renal or hepatic disease diabetes mellitus BMI less than 18 kg/m2 or greater than 25 kg/m2
C: Inclusion Criteria:

* Age 18 years of age
* Evidence of CTEPH
* Acceptable surgical candidate

Exclusion Criteria:

* BMI \> 40
* Patient undergoing lung biopsy or CABG at time of surgery
D: Inclusion Criteria:

* Planned intrabdominal surgery
* Expected duration ≥ 2 hours
* Age ≥ 40 yr (and \<90 yr)
* Risk of postoperative pulmonary complications (Arozullah score ≥2)

Exclusion Criteria:

* Noninvasive ventilation in the last 30 days
* Recent history of pneumonia, ALI/ARDS (in the last 30 days)
* History of pulmonary resection
* History of neuromuscular disease
* Patient refusal

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Web and Mobile Smoking Cessation Interventions
Brief Summary: This study seeks to develop and then perform a controlled efficacy Randomized Controlled Trial assessing tobacco abstinence of a best-practices Web-based PC-delivered smoking cessation intervention (QuitOnline) compared to a Mobile Smartphone-delivered intervention (MobileQuit). Study participants are randomized to one of two conditions: a Web Only intervention and the Web+Mobile intervention. The hypothesis is that the Web+Mobile approach will yield greater efficacy than the Web Only condition.


Options:
A: Inclusion Criteria:

* ≥ 18 years of age
* Cigarettes are primary tobacco of use
* Smoke ≥ 5 cigs/day for the previous 6 months
* Want to quit in next 14 days
* Use a smartphone and willing to potentially receive/send up to 150 text messages over the six months of the program
* Access to the Internet
* Have a valid personal e-mail address
* Be a U.S. citizen
B: Inclusion Criteria:

* Age 19 to 29 years
* Currently smoking cigarettes daily or occasionally
* Residing in Canada
* Considering quitting smoking in the next 30 days
* Have an Android or iPhone OS smartphone
* Able to provide informed consent
* English comprehension
* Not referred by a study participant

Exclusion Criteria:

- opposite of the above
C: Inclusion Criteria:

* Students from Germany aged 9 to 14 years at baseline attending grades six and seven of regular German secondary schools (such as grammar, general, intermediate or comprehensive school) are eligible.

Exclusion Criteria:

* Older or younger pupils or pupils from other school types or countries or schools who previously participated in an event where the Smokerface app was presented are not eligible.
D: Inclusion Criteria:

* Pregnant and less than 25 weeks gestation
* Smoking at least 5 cigarettes per day pre-pregnancy
* Smoking at least 1 cigarette on a typical day during pregnancy
* Aged 16 or over
* Agrees to accept information to assist cessation
* Has own or has primary use of a mobile phone
* Familiar with sending and receiving text messages
* Able to understand written English (text messages are in English only) and consent issues explained in English.
* Able to give informed consent

Exclusion Criteria:

•Already enrolled in another text service to assist smoking cessation

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy of Dialectical Behavior Therapy in Patients With Borderline Personality Disorder: a Controlled Trial in Taiwan
Brief Summary: The purpose of this study is to test the hypothesis:

Primary hypothesis: Participants in the dialectical behavior therapy group have greater reductions in the frequency and severity of suicidal and non-suicidal self-injurious behaviors compared to participants in the alternative treatment group.

Secondary Hypotheses: Participants in dialectical behavior therapy group have improved treatment outcomes compared to participants in alternative treatment, including mental health service utilization, symptoms of borderline personality and depression symptoms, suicidal thought and hopelessness, disability, and quality of life.


Options:
A: Inclusion Criteria:

* in inpatient mental health treatment
* report a suicide attempt in the past month
* have a primary caretaker willing to participate in aftercare
* are able to travel to CHOP
* have no history of psychosis or low intellectual capacity
* speak adequate English.

Exclusion Criteria:

* being discharged to a residential placement
B: Inclusion Criteria:

* Identifies as an African-American female
* Abusive relationship within the 12 months prior to study entry
* Suicide attempt within the 12 months prior to study entry
* Seeks services at Grady Health System

Exclusion Criteria:

* Score of less than 22 on Mini Mental Status Exam (MMSE)
* Score of less than 18 on Rapid Estimate of Adult Literacy in Medicine (REALM)
* Acutely psychotic
C: Inclusion Criteria:

* meeting DSM-IV criteria for borderline personality disorder
* 18-60 years of age
* have had at least two episodes of suicidal or non-suicidal self-injurious episodes in the past 5 years,
* at least one episode of suicidal is in the 3 months preceding enrollment
* agreement to participate in evaluation of the program.

Exclusion Criteria:

* bipolar I disorder, delirium, dementia, mental retardation, or a diagnosis of substance dependence in the preceding 30 days
* living outside of Taipei area
* having any serious medical condition likely to require hospitalization within the next year (e.g. cancer)
* and having plans to leave the Taipei area in the next 1 year
D: Inclusion Criteria:

* Current psychiatric inpatients
* Possess an active email account
* Informed consent
* Active duty military, Veteran, Retiree, National Guard or Reserves status

Exclusion Criteria:

* Not competent to consent
* Adverse behavioral problems
* The primary psychiatric nurse or attending psychiatrist considers that study to be clinically inappropriate
* Currently under arrest/incarceration
* Involuntary committed for psychiatric care status

Answer: C